Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211040 | 0.72 | KIF11 (0.42) | ALDH1A1KMT2ALMNAHTTMEN1 | |
| SCHEMBL5669762 | 0.71 | ALDH1A1 (0.44) | ALDH1A1KMT2ALMNAHTTGLA | |
| SCHEMBL5669770 | 0.71 | ALDH1A1 (0.44) | ALDH1A1KMT2ALMNAHTTGLA | |
| SCHEMBL27500132 | 0.69 | KMT2A (0.44) | ALDH1A1KMT2ALMNAHTTGLA | |
| SCHEMBL625122 | 0.69 | KMT2A (0.44) | ALDH1A1KMT2ALMNAHTTGLA | |
| SCHEMBL14691647 | 0.68 | NPSR1 (0.44) | ALDH1A1KMT2ALMNAHTTGLA | |
| SCHEMBL5347581 | 0.66 | NPSR1 (0.39) | ALDH1A1KMT2ALMNAHTTGLA | |
| SCHEMBL6180241 | 0.66 | NPSR1 (0.39) | ALDH1A1KMT2ALMNAHTTGLA | |
| SCHEMBL421668 | 0.66 | NPSR1 (0.39) | ALDH1A1KMT2ALMNAHTTGLA | |
| SCHEMBL5322296 | 0.65 | NPSR1 (0.41) | ALDH1A1KMT2AHTTGLATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2011-07-21 | — | — | US | claimed |
| EP-2451776-B1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING INC (US) | 2019-09-18 | — | — | EP | disclosed |
| US-9732047-B2 | N-alkoxyamide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| EP-2240206-B1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170029386-A9 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-9393329-B2 | N-alkoxyamide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160185737-A1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-9266846-B2 | N-alkoxyamide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9217009-B2 | Version of FDG detectable by single-photon emission computed tomography | MALLINCKRODT LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150094465-A1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| EP-1068224-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | Du Pont Pharmaceuticals Company (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-2000035488-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| EP-0999856-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | Du Pont Pharmaceuticals Company (US) | 2000-05-17 | — | — | EP | disclosed |
| US-6015904-A | HYDRAZONE-MODIFIED BIOLOGICALLY ACTIVE MOLECULES WHICH REACT WITH GAMMA-EMITTING RADIOISOTOPES AND FORM COMPOUNDS WHICH SELECTIVELY BIND AT DISEASE SITES FOR IMAGING BY GAMMA SCINTIGRAPHY | LANTHEUS MEDICAL IMAGING, INC. | 2000-01-18 | — | — | US | disclosed |
| US-6010679-A | TRANSITION METAL RADIONUCLEOLIDE; CONTRAST AGENTS FOR DIAGNOSING CARDIOVASCULAR DISORDERS, CANCER | LANTHEUS MEDICAL IMAGING, INC. | 2000-01-04 | — | — | US | disclosed |
| WO-1999058162-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-11-18 | — | — | WO | disclosed |
| US-5879659-A | IMAGES FOR DIAGNOSIS OF CARDIOVASCULAR DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-03-09 | — | — | US | disclosed |
| US-5750088-A | IMAGING AGENTS FOR DIAGNOSIS OF CARDIOVASCULAR DISORDERS,INFECTIONS, INFLAMMATION, CANCER | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-05-12 | — | — | US | disclosed |
| US-5744120-A | PHOSPHINE OR ARSINE LIGATED TECHNETIUM-99M LABELED HYDRAZINO OR DIAZINO MODIFIED BIOLOGICALLY ACTIVE MOLECULES THAT SELECTIVELY LOCALIZE AT SITES OF DISEASE | THE DUPONT MERICK PHARMACEUTICAL COMPANY (US) | 1998-04-28 | — | — | US | disclosed |
| WO-1998015295-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | SLC2A1, SLC2A4, SLC2A3 | ALDH1A1 959/4885KMT2A 2498/4885LMNA 4406/4885 |
| US-20150094465-A1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | TNNT2, UACA, ELANE | ALDH1A1 1479/4885KMT2A 1880/4885LMNA 41/4885 |
| US-20170029386-A9 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | TNNT2, UACA, ELANE | ALDH1A1 1479/4885KMT2A 1880/4885LMNA 41/4885 |
| US-20160185737-A1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | TNNT2, UACA, ELANE | ALDH1A1 1479/4885KMT2A 1880/4885LMNA 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.